(a)  ,

(b)  , or

(c)  ;

W is $NHC(=X)R_1$, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection (b);

Y is NH, O, or S;

Z is $S(=O)(=N\text{-}R_5)$;

R_1 is

(a) H,

(b) NH_2,

(c) $NHC_{1\text{-}4}$alkyl,

(d) $C_{1\text{-}4}$alkyl,

(e) $C_{2\text{-}4}$alkenyl,

(f) $OC_{1\text{-}4}$alkyl,

(g) $SC_{1\text{-}4}$alkyl, or

(h) $(CH_2)_p C_{3\text{-}6}$cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R_1 is optionally substituted with one or more F, Cl or CN;

R_2 and R_3 are independently H, F, Cl, methyl or ethyl;

R_4 is H, CH_3, or F;

R_5 is

(c) $C(=O)C_{1\text{-}4}$alkyl,

(d) $C(=O)OC_{1-4}$alkyl,

(e) $C(=O)NHR_6$, or

(f) $C(=S)NHR_6$;

C1 E1 cont

R_6 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, alkyl in R_5 and R_6 is optionally substituted with one or more halo, CN, NO_2, phenyl, C_{3-6} cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, NR_7R_7, oxo, or oxime;

R_7 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF_3, CH_3, CN, NO_2, phenyl, C_{3-6} cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2; and

n is 2 or 3.

C2 9. (ONCE AMENDED) A compound of claim 2-7 wherein X is an oxygen atom.

C3 16. (ONCE AMENDED) A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

C4 47. (ONCE AMENDED) A compound of formula II

C4
E1
cont



II

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii



ii ;

B is



;

W is NHC(=X)R_1, or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is S(=O)(=N-R_5) and the B ring has the following stereochemistry



;

R_1 is

(a) H,

(b) NH_2,

(c) NHC_{1-4}alkyl,

C4
E1
cont

(d) C_{1-4}alkyl,

(e) C_{2-4}alkenyl,

(f) OC_{1-4}alkyl,

(g) SC_{1-4}alkyl, or

(h) $(CH_2)_pC_{3-6}$cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R_1 is optionally substituted with one or more F, Cl or CN;

R_2 and R_3 are independently H, F, Cl, methyl or ethyl;

R_4 is H, CH_3, or F;

R_5 is

(a) H,

(b) C_{1-4}alkyl,

(c) $C(=O)C_{1-4}$alkyl,

(d) $C(=O)OC_{1-4}$alkyl,

(e) $C(=O)NHR_6$, or

(f) $C(=S)NHR_6$;

R_6 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, alkyl in R_5 and R_6 is optionally substituted with one or more halo, CN, NO_2, phenyl, C_{3-6}cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, NR_7R_7, oxo, or oxime;

R_7 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF_3 CH_3, CN, NO_2, phenyl, C_{3-6}cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2.

C5 54. (ONCE AMENDED) The compound of claim 47 wherein X is an oxygen atom.

C6 E1 cont 65. (TWICE AMENDED) A compound of claim 47 which is

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{[(methylamino)carbonyl]imino}-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;